Phathom Pharmaceuticals, Inc. EBITDA

EBITDA of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBITDA growth rates and interactive chart. Earnings before interest, tax, depreciation and amortization (EBITDA) is a measure of a company's operating performance. Essentially, it's a way to evaluate a company's performance without having to factor in depreciation, interest expenses (debt), writedowns or other accounting measures and taxes. EBITDA, however, can be misleading because it strips out the cost of capital investments like property, plant, and equipment. To calculate EBITDA, take operating profit (also called EBIT) and add back depreciation and amortization.

Highlights and Quick Summary

  • EBITDA for the quarter ending September 29, 2021 was $-33 Million (a -6.2% decrease compared to previous quarter)
  • Year-over-year quarterly EBITDA decreased by -36.96%
  • Annual EBITDA for 2020 was $-125 Million (a 359.04% increase from previous year)
  • Annual EBITDA for 2019 was $-27.3 Million (a 2129.39% increase from previous year)
  • Twelve month EBITDA ending September 29, 2021 was $-154 Million (a 0.17% increase compared to previous quarter)
  • Twelve month trailing EBITDA increased by 23.38% year-over-year
Trailing EBITDA for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$-154 Million $-154 Million $-138 Million $-125 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBITDA of Phathom Pharmaceuticals, Inc.

Most recent EBITDAof PHAT including historical data for past 10 years.

Interactive Chart of EBITDA of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. EBITDA for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-33.01 $-35.19 $-33.46
2020 $-52.36 $-32.74 $-19.6 $-20.12 $-125.37
2019 $-15.52 $-6.12 $-83.01 $-1.23 $-27.31
2018 $-0.27 $-1.23

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.